Phosphoramidic Acid

Phosphoramidic Acid

SCHEMBL111868

NP(=O)(O)O.Nc1ncnc2c1ncn2[C@@H]1O[C@H](C(O)N(CCCC(=O)O)CCCC(=O)O)[C@@H](O)[C@H]1O

nearest known ligand 0.57

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GNMT Q14749 1/20 0.56
PRKACA P17612 1/20 0.55
AHCY P23526 2/20 0.55
HIF1A Q16665 1/20 0.55
TMEM97 Q5BJF2 1/20 0.55
SIGMAR1 Q99720 1/20 0.55
QARS1 P47897 1/20 0.55
P2RY1 P47900 3/20 0.51
DNPH1 O43598 1/20 0.51
PRKAB2 O43741 1/20 0.51
TRPM2 O94759 1/20 0.51
LDHA P00338 1/20 0.51
ADRB2 P07550 1/20 0.51
FBP1 P09467 1/20 0.51
SRC P12931 1/20 0.51
ADORA1 P30542 1/20 0.51
P2RY2 P41231 1/20 0.51
PRKAG1 P54619 1/20 0.51
PRKAA2 P54646 1/20 0.51
PDE4D Q08499 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Phosphoramidic Acid SCHEMBL109493 0.95 QARS1 (0.56) PRKACAAHCYHIF1ATMEM97SIGMAR1
Phosphoramidic Acid SCHEMBL110548 0.90 AHCY (0.56) AHCYHIF1ATMEM97SIGMAR1QARS1
Phosphoramidic Acid SCHEMBL2690062 0.85 POLB (0.49) GNMTPRKACAAHCYHIF1ATMEM97
Phosphoramidic Acid SCHEMBL109796 0.84 NT5E (0.52) NT5E
SCHEMBL14696726 0.82 PRKACA (0.61) GNMTPRKACAAHCYHIF1ATMEM97
SCHEMBL14696483 0.81 PRKACA (0.65) GNMTPRKACAAHCYHIF1ATMEM97
SCHEMBL14696395 0.81 PRKACA (0.65) GNMTPRKACAAHCYHIF1ATMEM97
Phosphoramidic Acid SCHEMBL112033 0.80 NT5E (0.53) NT5E
Phosphoramidic Acid SCHEMBL109783 0.80 POLB (0.50) PRKACAQARS1P2RY1DNPH1PRKAB2
SCHEMBL6900339 0.78 AHCY (0.60) PRKACAAHCYHIF1ATMEM97SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120108533-A1 NOVEL PHOSPHATE MODIFIED NUCLEOSIDES USEFUL AS SUBSTRATES FOR POLYMERASES AND AS ANTIVIRAL AGENTS KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) 2012-05-03 US disclosed
EP-2424874-A1 NOVEL PHOSPHATE MODIFIED NUCLEOSIDES USEFUL AS SUBSTRATES FOR POLYMERASES AND AS ANTIVIRAL ANGENTS Katholieke Universiteit Leuven, K.U. Leuven R&D (BE) 2012-03-07 EP disclosed
WO-2010125200-A1 NOVEL PHOSPHATE MODIFIED NUCLEOSIDES USEFUL AS SUBSTRATES FOR POLYMERASES AND AS ANTIVIRAL ANGENTS KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) 2010-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120108533-A1 NOVEL PHOSPHATE MODIFIED NUCLEOSIDES USEFUL AS SUBSTRATES FOR POLYMERASES AND AS ANTIVIRAL AGENTS PNP, TYMP, MTAP GNMT 1907/4885PRKACA 1534/4885AHCY 1995/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.